Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPL | P06858 | 6/20 | 0.40 |
| ▸ | LIPG | Q9Y5X9 | 6/20 | 0.40 |
| ▸ | IMPDH2 | P12268 | 2/20 | 0.40 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.34 |
| ▸ | MAPK14 | Q16539 | 6/20 | 0.33 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | ATAD2 | Q6PL18 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1006183 | 0.87 | LIPG (0.53) | LPLLIPGMAPK1MAPT | |
| SCHEMBL29362504 | 0.87 | LIPG (0.53) | LPLLIPGMAPK1MAPT | |
| SCHEMBL29581600 | 0.85 | PDE10A (0.34) | LPLLIPGIMPDH2TGFBR1MAPK1 | |
| SCHEMBL18788571 | 0.85 | PDE10A (0.34) | LPLLIPGIMPDH2TGFBR1MAPK1 | |
| SCHEMBL16473593 | 0.84 | LIPG (0.59) | LPLLIPGMAPT | |
| SCHEMBL19713462 | 0.84 | LPL (0.44) | LPLLIPGHTTHSD17B10RAB9A | |
| SCHEMBL23957176 | 0.83 | LPL (0.46) | LPLLIPGMAPK1 | |
| SCHEMBL13855171 | 0.83 | LPL (0.46) | LPLLIPGMAPK1 | |
| SCHEMBL22139774 | 0.83 | LIPG (0.62) | LPLLIPG | |
| SCHEMBL1505886 | 0.83 | LPL (0.45) | LPLLIPGMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10854823-B2 | Heterocyclic compound and organic light-emitting device including the same | SAMSUNG DISPLAY CO., LTD. (KR) | 2020-12-01 | — | — | US | disclosed |
| US-20180198074-A1 | HETEROCYCLIC COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE SAME | SAMSUNG DISPLAY CO., LTD. (KR) | 2018-07-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10854823-B2 | Heterocyclic compound and organic light-emitting device including the same | CRY1, CRY2, CYP1A1 | LPL 2980/4885LIPG 3765/4885IMPDH2 1381/4885 |
| US-20180198074-A1 | HETEROCYCLIC COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE SAME | CRY1, CRY2, CYP1A1 | LPL 2980/4885LIPG 3765/4885IMPDH2 1381/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.